Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SOX9 drives WNT pathway activation in prostate cancer
Fen Ma, … , Steven P. Balk, Xin Yuan
Fen Ma, … , Steven P. Balk, Xin Yuan
Published April 4, 2016
Citation Information: J Clin Invest. 2016;126(5):1745-1758. https://doi.org/10.1172/JCI78815.
View: Text | PDF
Research Article Oncology

SOX9 drives WNT pathway activation in prostate cancer

  • Text
  • PDF
Abstract

The transcription factor SOX9 is critical for prostate development, and dysregulation of SOX9 is implicated in prostate cancer (PCa). However, the SOX9-dependent genes and pathways involved in both normal and neoplastic prostate epithelium are largely unknown. Here, we performed SOX9 ChIP sequencing analysis and transcriptome profiling of PCa cells and determined that SOX9 positively regulates multiple WNT pathway genes, including those encoding WNT receptors (frizzled [FZD] and lipoprotein receptor-related protein [LRP] family members) and the downstream β-catenin effector TCF4. Analyses of PCa xenografts and clinical samples both revealed an association between the expression of SOX9 and WNT pathway components in PCa. Finally, treatment of SOX9-expressing PCa cells with a WNT synthesis inhibitor (LGK974) reduced WNT pathway signaling in vitro and tumor growth in murine xenograft models. Together, our data indicate that SOX9 expression drives PCa by reactivating the WNT/β−catenin signaling that mediates ductal morphogenesis in fetal prostate and define a subgroup of patients who would benefit from WNT-targeted therapy.

Authors

Fen Ma, Huihui Ye, Housheng Hansen He, Sean J. Gerrin, Sen Chen, Benjamin A. Tanenbaum, Changmeng Cai, Adam G. Sowalsky, Lingfeng He, Hongyun Wang, Steven P. Balk, Xin Yuan

×

Figure 4

Validation of SOX9-regulated expression of WNT pathways genes and activity in vitro and in vivo.

Options: View larger image (or click on image) Download as PowerPoint
Validation of SOX9-regulated expression of WNT pathways genes and activi...
(A) Levels of WNT components were measured by qRT-PCR in VCaP cells transfected with SOX9i or control siRNA. The relative mRNA levels are shown as fold change between SOX9i and nontargeting control (NTC). For each gene, one bar represents one primer set (some genes were assessed with two independent primer sets; see the Supplemental Methods for primer sequences). (B) Levels of WNT5A were measured by qRT-PCR in VCaP cells transfected with siRNA (SOX9i) or in a stable VCaP cell line overexpressing SOX9 (SOX9-OE). The results are presented as the fold change compared with their corresponding controls. (C) Levels of SOX9 and WNT components were measured by qRT-PCR in 5 LNCaP SOX9-OE xenografts derived from a LNCaP cell line with inducible SOX9 overexpression (SOX9-OE, n = 5). The relative mRNA levels are shown as fold change between SOX9-OE and uninduced control. The numbers 1–5 indicate results from 5 independent xenografts. (D) Levels of SOX9 and WNT components were measured by qRT-PCR in 5 CWR22Rv1 xenografts derived from a stable SOX9 shRNA expressing cell line (shSOX9, n = 5). The relative mRNA levels are shown as fold change between shSOX9 and control. All error bars represent SD.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts